EUVIMEDOtkrijte EUVIMED
Crossref

Adapting a Monoclonal Antibody (mAb) Facility for Gene Therapy Production

Alfred Penfold

EJPPS - European Journal of Parenteral and Pharmaceutical Sciences · 2026-07-02

DOI: 10.37521/ejpps31206 ↗

At a glance

Journal article in EJPPS - European Journal of Parenteral and Pharmaceutical Sciences, published online on 2026-07-02. Written by Alfred Penfold. 2 references.

SažetakBibliografski podaciCiteRelated studies

Abstract (original language)

Biopharmaceutical manufacturers are increasingly challenged to support a rapidly expanding therapeutic landscape where monoclonal antibodies (mAbs), viral vector gene therapies, and other advanced modalities must be produced with agility, regulatory compliance, and cost efficiency. Traditionally, manufacturers have built dedicated facilities for each modality due to differences in biosafety classification, process flow, contamination risks, and cleanroom requirements. However, this approach is no longer sustainable in a climate of increased development activities and economic pressure. A detailed feasibility study was undertaken to examine whether an existing GMP compliant mAb Drug Substance facility could be successfully adapted for the manufacture of viral vector based gene therapies. The study considered technical, regulatory, biosafety, operational, and risk elements, and included engagement with the U.S. FDA to review the containment strategy, process flows, and facility layout. The core finding is that mAb and gene therapy processes exhibit strikingly similar equipment, operational stages, and facility needs, allowing for significant reuse of existing infrastructure. The primary challenge, and the main differentiator, is the requirement for BSL 2, or BSL 2 Large Scale (LS), containment for gene therapy production, along with additional procedural controls and enhanced biosafety waste streams. Upgrades, including targeted HVAC modifications, the installation of isolator technology for helper virus handling, improvements to waste treatment processes, and the implementation of comprehensive single use systems, were evaluated and found both feasible and efficient. Ultimately, the feasibility study demonstrates that dual modality manufacturing of mAbs and gene therapy vectors within the same facility is indeed viable, compliant, and operationally efficient, provided that a comprehensive risk based, engineering led approach is applied.

Cite

APA

Penfold, A. (2026). Adapting a Monoclonal Antibody (mAb) Facility for Gene Therapy Production. EJPPS - European Journal of Parenteral and Pharmaceutical Sciences. https://doi.org/10.37521/ejpps31206

Vancouver

Penfold A. Adapting a Monoclonal Antibody (mAb) Facility for Gene Therapy Production. EJPPS - European Journal of Parenteral and Pharmaceutical Sciences. 2026. doi:10.37521/ejpps31206

BibTeX
@article{Penfold2026,
  author = {Penfold, Alfred},
  title = {Adapting a Monoclonal Antibody (mAb) Facility for Gene Therapy Production},
  journal = {EJPPS - European Journal of Parenteral and Pharmaceutical Sciences},
  year = {2026},
  doi = {10.37521/ejpps31206}
}
Start for free →